Development
Boston Scientific Corporation
BSX
$102.09
-$0.74-0.72%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 260.00% | 168.09% | 3.85% | 185.45% | 47.37% |
| Total Depreciation and Amortization | 6.46% | 5.63% | 4.93% | 4.01% | 1.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 405.13% | -76.82% | -10.34% | -52.50% | -69.53% |
| Change in Net Operating Assets | -117.07% | 42.11% | 96.03% | 23.31% | 1,054.29% |
| Cash from Operations | 18.59% | 48.51% | 114.33% | 427.59% | 68.83% |
| Capital Expenditure | -25.94% | -26.67% | -36.19% | 8.26% | 20.30% |
| Sale of Property, Plant, and Equipment | -100.00% | 0.00% | -100.00% | -62.50% | -50.00% |
| Cash Acquisitions | -- | 100.00% | -- | 74.51% | 100.00% |
| Divestitures | -- | -- | -- | -- | -80.00% |
| Other Investing Activities | -68.18% | -60.00% | -172.00% | -110.00% | 10.00% |
| Cash from Investing | -475.41% | 12.44% | -2,796.55% | 69.25% | 60.30% |
| Total Debt Issued | -- | 75.97% | 152.86% | -- | -- |
| Total Debt Repaid | -- | -300.00% | -- | -- | -- |
| Issuance of Common Stock | -10.53% | 27.12% | 350.00% | 21.15% | 137.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Other Financing Activities | 60.00% | 79.78% | 97.37% | -13.46% | -66.67% |
| Cash from Financing | 1,400.00% | 108.04% | 112.50% | -1,050.00% | 112.50% |
| Foreign Exchange rate Adjustments | 33.33% | 16.67% | 50.00% | -- | 400.00% |
| Miscellaneous Cash Flow Adjustments | -- | 200.00% | -200.00% | -- | 0.00% |
| Net Change in Cash | -112.24% | 1,215.38% | -101.41% | 77.85% | 6,888.89% |